Ignite Creation Date:
2024-07-17 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06477536
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-22
Brief Title:
Long-Term Safety and Efficacy of HB0034 in Subjects with Generalized Pustular Psoriasis
Sponsor:
Shanghai Huaota Biopharmaceutical Co Ltd
Organization:
Shanghai Huaota Biopharmaceutical Co Ltd
Study Overview
Official Title:
A Phase 3 Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects with Generalized Pustular Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IIb long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis GPP
Detailed Description:
This study will also evaluate the pharmacokinetic PK profile of HB0034 and explore the immunogenicity of HB0034 in subjects with GPP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None